NA Colorectal Cancer Screening Tests Market Analysis | 2035

What are the Best Colorectal Cancer Screening Options in North America?

The question of which screening method is most effective and accessible is at the heart of the North America colorectal cancer screening tests market. As colorectal cancer (CRC) remains the second leading cause of cancer-related deaths in the United States and Canada, the push for early detection has never been more urgent. With advancements in non-invasive technology and a shift in clinical guidelines, the landscape of screening is changing rapidly.

Market Overview: A Decade of Growth

The North America colorectal cancer screening tests market is currently navigating a transformative era. In 2025, the market was valued at USD 6.27 billion. Driven by an aging population, rising awareness, and a significant lowering of the recommended screening age, the market is projected to grow at a CAGR of 5.60% during the forecast period of 2026–2035. By 2035, the market value is expected to reach approximately USD 10.81 billion.

This growth isn’t just about volume; it’s about variety. While colonoscopies remain the “gold standard,” there is a massive surge in demand for patient-friendly, stool-based alternatives that allow for home-based testing. This shift is critical for increasing compliance rates across diverse socioeconomic populations.

Key Growth Drivers: Why the Market is Expanding

Several systemic and demographic factors are propelling the North America colorectal cancer screening tests market forward:

• Lowering of Screening Age Guidelines: The United States Preventive Services Task Force (USPSTF) recently lowered the recommended starting age for CRC screening from 50 to 45 for average-risk individuals. This has instantly added millions of eligible adults to the screening pool.
• Rise in Early-Onset Colorectal Cancer: There is a documented increase in CRC cases among adults under 50. This alarming trend has catalyzed both public health campaigns and private sector innovation.
• Technological Advancements in Liquid Biopsies: The development of blood-based screening tests (liquid biopsies) that detect circulating tumor DNA (ctDNA) is a major market driver. These tests promise a higher level of patient adherence compared to invasive procedures.
• Favorable Reimbursement Landscapes: In the U.S., the Affordable Care Act (ACA) and Medicare have expanded coverage for various screening modalities, reducing out-of-pocket costs for patients and encouraging regular testing.
• Post-Pandemic Shift to At-Home Care: The COVID-19 pandemic accelerated the acceptance of “mail-in” stool tests like FIT and Stool DNA tests, as patients became more comfortable with self-collection.

Market Segmentation by Screening Tests

The North America colorectal cancer screening tests market is segmented by technology, each serving different clinical needs and patient preferences.

1. Stool-Based Tests

Stool-based tests are the fastest-growing segment due to their non-invasive nature and cost-effectiveness.

• Fecal Immunochemical Test (FIT): Uses antibodies to detect blood in the stool. It is highly specific and does not require dietary restrictions.
• Fecal Occult Blood Test (FOBT): The traditional chemical-based test. While still used, it is gradually being replaced by the more accurate FIT.
• Stool DNA Test: Exemplified by products like Cologuard, this test looks for both blood and DNA biomarkers associated with precancerous polyps and cancer. It has seen massive adoption in the U.S. market.

2. Colonoscopy

Colonoscopy remains the most comprehensive tool because it allows for both detection and immediate removal of polyps (polypectomy). Despite being invasive and requiring bowel preparation, its role as a diagnostic and preventive tool ensures it holds a dominant share of the market value.

3. CT Colonography (Virtual Colonoscopy)

This uses CT scans to create 3D images of the colon. It is an alternative for patients who cannot undergo a traditional colonoscopy, though it still requires bowel prep and a follow-up invasive procedure if a polyp is found.

4. Flexible Sigmoidoscopy and Others

While less common now, sigmoidoscopy remains an option for specific patient profiles. Emerging “others” include blood-based biomarkers and AI-enhanced endoscopic tools.

Regional Analysis: United States vs. Canada

The United States of America

The U.S. accounts for the lion’s share of the North American market. This is due to a highly developed healthcare infrastructure, aggressive marketing by companies like Exact Sciences, and a robust insurance system that incentivizes preventive care. The U.S. market is also the primary hub for R&D in molecular diagnostics.

Canada

Canada’s market is characterized by provincial screening programs that emphasize FIT as the primary screening tool for average-risk populations. While the growth rate is steady, the Canadian market focuses more on public health efficiency and reducing the backlog for colonoscopy wait times through better triaging with stool-based tests.

Key Drivers of the North America Colorectal Cancer Screening Market!
Get insights, growth metrics & trends—download your free report!

Market Trends to Watch (2026–2035)

As we move into the forecast period, several trends will define the industry:

• AI-Assisted Colonoscopy: Artificial Intelligence (AI) is being integrated into endoscopic hardware to help gastroenterologists spot tiny or flat polyps that might be missed by the human eye.
• Blood-Based Screening (Liquid Biopsies): Companies are racing to perfect a blood test that can match the sensitivity of stool DNA tests. If successful, this could revolutionize the North America colorectal cancer screening tests market by making screening as simple as a routine blood draw.
• Personalized Screening Intervals: Using genetic risk scores to determine how often a person should be screened, rather than a “one size fits all” approach based on age.
• Digital Health Integration: Diagnostic centers are increasingly using apps to remind patients of screening intervals and to help them navigate bowel preparation.

Major Key Players

The competitive landscape is dominated by a mix of established diagnostic giants and innovative biotech firms:

• Exact Sciences Corporation: The leader in stool DNA testing.
• Abbott Laboratories & Roche Diagnostics: Providers of high-throughput FIT and laboratory-based testing systems.
• Siemens AG & Siemens Healthineers: Leaders in imaging technology for CT colonography.
• Laboratory Corporation of America® Holdings (LabCorp): A major provider of diagnostic services across the continent.
• LetsGetChecked: Representing the rise of direct-to-consumer at-home testing kits.

Challenges and Barriers to Entry

Despite the positive outlook, the North America colorectal cancer screening tests market faces hurdles:

• Patient Compliance: Despite the availability of tests, a significant portion of the eligible population remains unscreened due to “fear of the procedure” or lack of awareness.
• Accuracy Concerns: Non-invasive tests can yield false positives, leading to unnecessary anxiety and follow-up colonoscopies, or false negatives, providing a false sense of security.
• High Cost of Advanced Tests: While FIT is inexpensive, stool DNA and blood-based tests are significantly more costly, which can strain public health budgets.

Future Outlook: Moving Toward Eradication

The long-term goal of the North America colorectal cancer screening tests market is to move from “cancer detection” to “cancer prevention.” By identifying and removing polyps before they turn into malignancy, the industry has the potential to virtually eliminate CRC as a major cause of death.

Between 2026 and 2035, expect a surge in “multi-modal” screening, where patients utilize a combination of annual non-invasive tests and decennial colonoscopies, supported by AI-driven risk assessment.

FAQs

1. What is the expected growth of the North America colorectal cancer screening tests market?

The North America colorectal cancer screening tests market is projected to grow at a CAGR of 5.60% from 2026 to 2035. Starting at a value of USD 6.27 billion in 2025, it is expected to reach USD 10.81 billion by the end of the forecast period.

2. Which segments are driving the North America colorectal cancer screening tests market?

The market is primarily driven by the stool-based tests segment (specifically FIT and stool DNA tests) and the colonoscopy segment. The shift toward non-invasive, at-home testing options is a significant contributor to the increasing market volume.

3. At what age should I start colorectal cancer screening in North America?

Current clinical guidelines in the U.S. and increasingly in Canada recommend that individuals at average risk start regular screening at age 45. Those with a family history of CRC or certain genetic conditions may need to start earlier.

4. Is an at-home stool test as good as a colonoscopy?

Stool tests are excellent for detecting cancer, but colonoscopies are superior for prevention because they allow doctors to remove polyps before they become cancerous. If an at-home test returns a positive result, a follow-up colonoscopy is mandatory.

5. Will insurance cover my colorectal cancer screening?

In the United States, most private insurance plans and Medicare cover the cost of screening tests for those aged 45 and older as a preventive service. In Canada, provincial health programs cover screening costs for eligible residents.

Explore More Reports

Premenopausal Advanced Breast Cancer Epidemiology Forecast

United States Medical Writing Market

United States Compounding Pharmacies Market

Speciality Generics Market

About Us:

Expert Market Research is a leading market research firm delivering data-driven insights to the pharmaceutical, biotechnology, and medical device industries. Our comprehensive research solutions include market research reports, providing in-depth analysis of industry trends and competitive landscapes; drug pipeline reports, tracking drug development progress, clinical trials, and regulatory approvals; epidemiology reports, offering detailed disease prevalence and patient population studies; and patent reports, assessing intellectual property landscapes and innovation trends, among others.

Leveraging proprietary data, advanced analytics, and expert methodologies, we help businesses navigate complex markets, optimize strategies, and drive innovation. We empower clients with actionable intelligence, enabling them to make informed decisions and stay ahead in the rapidly evolving healthcare sector.

Media Contact:

Company Name: Claight Corporation
Email: sales@expertmarketresearch.com
Toll-Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: www.expertmarketresearch.com